8 large- and mid-cap pharma stocks that have more than doubled in a year
Many of the large- and mid-cap pharma stocks have performed well in the last one year. Nifty Pharma Index has also been a good performer in the last one year with a 52.49% jump. The index's rise in the 3 and 5 years is 43.88% and 100.78%, respectively. Here, we take you through the performance of the large- and mid-cap pharma stocks which have doubled their value in the one-year period (As per Trendlyne data as on April 25, 2024).
Photos: Pixabay/Unsplash
Wockhardt
The mid-cap pharma firm is the top performer among all the large- and mid-cap companies. Its stock has skyrocketed by 250% in the 1-year period.
Lupin
The large-cap company is second in the list with a 129.05% rise in the 1 year.
Jubilant Pharma
This mid-cap pharma firm has given 126.44% return in the one year.
Concord Biotech
The biotech firm has also given nearly 125% returns at 124.29% in the 1 year.
Shilpa Medicare Ltd
The mid-cap firm's returns in the 1 year are 112.64%.
Glenmark Pharmaceuticals
The large-cap company's returns in the 1 year are 108.50%.
Piramal Pharma
The pharma firm at the No. 8 position has also given 106.19% returns.